[Efficacy of ceftriaxone against gynecoobstetric infections].
Ceftriaxone (Ro 13-9904, CTRX), a newly developed parenteral cephalosporin antibiotic was clinically evaluated in gynecoobstetric infections and the following results were obtained. CTRX was administered by intravenous drip infusion twice a day in a daily dose of 2 to 4 g to 10 cases with gynecoobstetric infections, consisting of 8 with intrauterine infections, 1 with adnexitis and 1 with infection of external genitalia. The global clinical efficacy was excellent in 2 and good in 6 out of 8 cases with intrauterine infections, and in 2 others, the efficacy rate being 100%. Bacteriologically, the eradication of bacteria was observed in 5, unchange in 2 and alternation of bacteria in 2 among 9 cases where the causative strains were detected. Neither adverse reaction nor laboratory test abnormality was observed. The above-mentioned results suggest that CTRX is a highly safe antibiotic expected to be excellent in the clinical efficacy and bacteriological effects.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002443:Ceftriaxone; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy; D014591:Uterine Diseases / Q000188:drug therapy*
D002443:Ceftriaxone; D002439:Cefotaxime